86 related articles for article (PubMed ID: 31996725)
1. Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes.
Li H; Zhang Q; Shuman L; Kaag M; Raman JD; Merrill S; DeGraff DJ; Warrick JI; Chen G
Sci Rep; 2020 Jan; 10(1):1439. PubMed ID: 31996725
[TBL] [Abstract][Full Text] [Related]
2. Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer.
Sweis RF; Spranger S; Bao R; Paner GP; Stadler WM; Steinberg G; Gajewski TF
Cancer Immunol Res; 2016 Jul; 4(7):563-8. PubMed ID: 27197067
[TBL] [Abstract][Full Text] [Related]
3. Age and sex have no impact on expression levels of markers of immune cell infiltration and immune checkpoint pathways in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy.
Holland BC; Sood A; Delfino K; Dynda DI; Ran S; Freed N; Alanee S
Cancer Immunol Immunother; 2019 Jun; 68(6):991-997. PubMed ID: 30997535
[TBL] [Abstract][Full Text] [Related]
4. Multiplexed immunofluorescence identifies high stromal CD68
Wang J; Browne L; Slapetova I; Shang F; Lee K; Lynch J; Beretov J; Whan R; Graham PH; Millar EKA
Sci Rep; 2021 Nov; 11(1):21608. PubMed ID: 34732817
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Impact and Spatial Interplay of Immune Cells in Urothelial Cancer.
Debatin NF; Bady E; Mandelkow T; Huang Z; Lurati MCJ; Raedler JB; Müller JH; Vettorazzi E; Plage H; Samtleben H; Klatte T; Hofbauer S; Elezkurtaj S; Furlano K; Weinberger S; Giacomo Bruch P; Horst D; Roßner F; Schallenberg S; Marx AH; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke TH; Hallmann S; Koch S; Adamini N; Lennartz M; Minner S; Simon R; Sauter G; Zecha H; Schlomm T; Blessin NC
Eur Urol; 2024 Jul; 86(1):42-51. PubMed ID: 38383257
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers.
Nakanishi J; Wada Y; Matsumoto K; Azuma M; Kikuchi K; Ueda S
Cancer Immunol Immunother; 2007 Aug; 56(8):1173-82. PubMed ID: 17186290
[TBL] [Abstract][Full Text] [Related]
7. Tumor immune microenvironment in odontogenic carcinomas: Evaluation of the therapeutic potential of immune checkpoint blockade.
Oh KY; Hong SD; Yoon HJ
J Oral Pathol Med; 2024 Mar; 53(3):217-225. PubMed ID: 38449350
[TBL] [Abstract][Full Text] [Related]
8. The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis.
Ahn J; Bishop JA; Roden RBS; Allen CT; Best SRA
Laryngoscope; 2018 Jan; 128(1):E27-E32. PubMed ID: 28940446
[TBL] [Abstract][Full Text] [Related]
9. Status of PD-1 and PD-L1 expression in invasive urothelial carcinoma of the bladder with mismatch repair protein deficiency.
Sungu N; Kıran MM
Pol J Pathol; 2023; 74(3):161-170. PubMed ID: 37955535
[TBL] [Abstract][Full Text] [Related]
10. Transcriptomic Profiling of Upper Tract Urothelial Carcinoma: Bladder Cancer Consensus Classification Relevance, Molecular Heterogeneity, and Differential Immune Signatures.
Fontugne J; Xylinas E; Krucker C; Dixon V; Groeneveld CS; Pinar U; Califano G; Bucau M; Verine J; Desgrandchamps F; Hermieu JF; Radvanyi F; Allory Y; Masson-Lecomte A
Mod Pathol; 2023 Nov; 36(11):100300. PubMed ID: 37558130
[TBL] [Abstract][Full Text] [Related]
11. POLQ identifies a better response subset to immunotherapy in muscle-invasive bladder cancer with high PD-L1.
Liu G; Jin K; Liu Z; Su X; Xu Z; Li B; Xu J; Chang Y; Wang Y; Zhu Y; Xu L; Xu J; Wang Z; Liu H; Zhang W
Cancer Med; 2024 Feb; 13(4):e6962. PubMed ID: 38457207
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of blocking novel immune checkpoint B7-H4 in urothelial carcinoma of bladder as a potential therapeutic target.
Raja D; Singh A; Kurra S; Nayak B; Kaushal S; Sharma A; Singh P
Med Oncol; 2024 Feb; 41(3):74. PubMed ID: 38376603
[TBL] [Abstract][Full Text] [Related]
13. Expression of tumoral GSK3-β, PD-L1, and CD8 cell density in urothelial carcinomas, association with tumor grade and overall survival.
Almeida Rodrigues AK; Silva PG; Nogueira C; Ferreira SS; Cordeiro J; Carneiro B; Tavora F
Am J Clin Exp Immunol; 2023; 12(5):87-97. PubMed ID: 38022872
[TBL] [Abstract][Full Text] [Related]
14. Distinct Infiltration of T Cell Populations in Bladder Cancer Molecular Subtypes.
Sincic V; Arlenhold KF; Richtmann S; Lilljebjörn H; Eriksson P; Sjödahl G; Wokander M; Hägerbrand K; Ellmark P; Fioretos T; Borrebaeck CAK; Liedberg F; Lundberg K
Cells; 2024 May; 13(11):. PubMed ID: 38891058
[TBL] [Abstract][Full Text] [Related]
15. Tumor microenvironment heterogeneity in bladder cancer identifies biologically distinct subtypes predicting prognosis and anti-PD-L1 responses.
Li Y; Liu Y; Kang Z; Guo J; Liu N
Sci Rep; 2023 Nov; 13(1):19563. PubMed ID: 37949863
[TBL] [Abstract][Full Text] [Related]
16. A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging.
Keren L; Bosse M; Marquez D; Angoshtari R; Jain S; Varma S; Yang SR; Kurian A; Van Valen D; West R; Bendall SC; Angelo M
Cell; 2018 Sep; 174(6):1373-1387.e19. PubMed ID: 30193111
[TBL] [Abstract][Full Text] [Related]
17. Treatment Strategies and Metabolic Pathway Regulation in Urothelial Cell Carcinoma: A Comprehensive Review.
Yang HY; Wu CY; Chen JJ; Lee TH
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33256165
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 Expression in Nonbacterial Chronic Cystitis and Bladder Cancer.
Kosova I; Barsegian V; Gundorova L; Kolbasov D
Int Urogynecol J; 2024 May; 35(5):1069-1075. PubMed ID: 38662109
[TBL] [Abstract][Full Text] [Related]
19. Methods to assess anticancer immune responses in orthotopic bladder carcinomas.
Sweis RF
Methods Enzymol; 2020; 635():127-137. PubMed ID: 32122541
[TBL] [Abstract][Full Text] [Related]
20. Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity.
Kato S; Okamura R; Kumaki Y; Ikeda S; Nikanjam M; Eskander R; Goodman A; Lee S; Glenn ST; Dressman D; Papanicolau-Sengos A; Lenzo FL; Morrison C; Kurzrock R
Oncoimmunology; 2020; 9(1):1708065. PubMed ID: 32117584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
